KLRC1 and neoplasm: Currently, immune checkpoint inhibitors (ICIs) have revolutionized tumour therapy, such as monacizumab targeting NKG2A inhibition to enhance NK cell and CD8 + T cell activity and further promote anti-tumor immunity [45], but ICIs still present a number of challenges.